Q4 2024 Boston Scientific Corp Earnings Call Transcript
Key Points
- Boston Scientific Corp (BSX) achieved a 23% growth in operational sales and a 20% growth in organic sales for Q4 2024, surpassing their guidance range.
- The company reported a 26% increase in adjusted EPS for Q4 2024, exceeding the high end of their guidance range.
- Strong performance in the Electrophysiology segment, with FARAPULSE leading the transformation of the AFib market, achieving over $1 billion in revenue globally in 2024.
- The Urology segment showed robust growth, driven by prosthetic urology and stone management, with key product launches contributing to this success.
- Boston Scientific Corp (BSX) anticipates continued strong financial performance in 2025, with expected organic growth of 10% to 12% for the full year and adjusted EPS growth of 12% to 14%.
- The company faces ongoing pricing pressures in China due to DBP, which could impact growth despite strong performance in the region.
- Increased competition from lower-cost competitors in some MedSurg businesses, particularly in Asia and Europe, poses a challenge.
- The Neuromodulation segment showed slower organic growth compared to operational growth, indicating potential areas for improvement.
- Boston Scientific Corp (BSX) anticipates a 200 to 300 basis point increase in the tax rate, which could impact EPS growth.
- The company is facing potential headwinds from tariffs and foreign exchange fluctuations, which have been factored into their guidance.
Good morning, and welcome to the Boston Scientific fourth quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Jon Monson, Senior Vice President, Investor Relations. Please go ahead.
Thank you, Drew, and thanks, everyone, for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Dan will be joined by our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q4 and full year 2024 results which included reconciliations of the non-GAAP measures used in this release.
The release as well as reconciliations of the non-GAAP measures used in today's call can be found on the Investor Relations section of our website. Please note that on the call, operational revenue excludes the impact of foreign currency
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
